$1,543,622
Total Seed Grants
Supporting Innovative New Research
Announcing 2024 Seed Grants for Early-Stage Research
We are now accepting letters of intent from researchers in the United States who are working on novel projects aimed at discovering new therapies and diagnostics for early detection of gastric cancer. Recipients will be awarded a one-time grant of up to $100,000. Up to two grants will be awarded this year.
Letters of intent should be submitted by email no later than March 29, 2024 to grants@gastriccancer.org.
Early-stage seed funding is extremely important because it enables researchers to generate sufficient preliminary data to submit compelling and competitive applications for large grants. It is often difficult for researchers to obtain this type of support. The Gastric Cancer Foundation has made early funding a special focus of its research strategy.
Targeting TGFβ signaling in gastric cancer: A biomarker-driven approach towards clinical translation
Kishore Guda, DVM, PhD
Case Western Reserve University School of Medicine
$100,000 granted in 2023
Targeting claudin 18.2-expressing gastric cancer using T cell antigen coupler (TAC)-T cells
Ryan Moy, MD, PhD
Columbia University Irving Medical Center
$100,000 granted in 2023
Identifying and targeting peritoneal-specific immunosuppresive networkls in gastric cancer from patient-derived samples
Alexandra-Chloé Villani, PhD
Massachusetts General Hospital
$100,000 granted in 2023
Pre-clinical project to evaluate the effects of SCD1 inhibition in GCK mouse stomachs and to determine whether the SCD1 inhibition can be a possible therapeutic intervention or treatment in patients with gastric dysplasia or early-stage cancer
Eunyoung Choi, PhD
Vanderbilt University Medical Center
$100,000 granted in 2022
The Oral Commensal Bacterium Fusobacterium Nucleatum as a Potential Driver of Gastric Cancer
Dr. Nina Salama, Ph.D.
Fred Hutchinson Cancer Research Center
$100,000 granted in 2021
Utilization of molecular evaluation of clinically-annotated patient samples and the application of single cell RNA-sequencing to strong in vitro model systems to understand the therapeutic potential of platinum chemotherapy and PARP inhibitors in HR-deficient gastric cancer
Nilay Sethi, MD, PhD
Dana-Farber/Harvard Cancer Center
$100,000 granted in 2022
Targeting Myeloid Cells to Enhance Immune Checkpoint Blockade in Gastric Cancer
Dr. Timothy C. Wang, M.D
Columbia University
$100,000 granted in 2021
Exploiting KMT2 as a Predictive Marker and Therapeutic Target in Advanced Gastric Cancer
Dr. Heinz-Josef Lenz
USC Norris Comprehensive Cancer Center
$75,000 Granted in 2020
New Targets and Therapies for Chromosomal Instability Underlying Gastric Cancer
Dr. Adam Bass
Dana-Farber Cancer Institute
$75,000 Granted in 2020
Interperitoneal Project to Develop New Therapies for Peritoneal Caricinomatosis
Dr. Jaffer Ajani
MD Anderson Cancer Center
$75,000 Granted in 2019
Study to Test Effectiveness of Combination Drug Therapy to Target Gastric Cancers with FGFR2 Defect and Prevent Drug Resistance
Dr. Hanlee Ji
Stanford Genome Technology Center
$30,104 Granted in 2019
Studying the Gastric Cancer Microenvironment Using Single Cell Genomics
Dr. Hanlee Ji
Stanford Genome Technology Center
$38,518 Granted in 2019
Use of Next-Generation DNA Sequencing Technology to Perform Whole-Genome Level Analysis on large Cohort of Individuals with Gastric Cancer
Dr. James Ford
Stanford University Medical School
$550,000 Total Grants 2010-2015
